Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine

Kane, John · 1988 · Archives of General Psychiatry

Abstract

The treatment of schizophrenic patients who fail to respond to adequate trials of neuroleptics is a major challenge. Clozapine, an atypical antipsychotic drug, has long been of scientific interest, but its clinical development has been delayed because of an associated risk of agranulocytosis. This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refractory to neuroleptics. DSM-III schizophrenics who had failed to respond to at least three different neuroleptics underwent a prospective, single-blind trial of haloperidol (mean dosage, 61 +/- 14 mg/d) for six weeks. Patients whose condition remained unimproved were then randomly assigned, in a double-blind manner, to clozapine (up to 900 mg/d) or chlorpromazine (up to 1800 mg/d) for six weeks. Two hundred sixty-eight patients were entered in the double-blind comparison. When a priori criteria were used, 30% of the clozapine-treated patients were categorized as responders compared with 4% of chlorpromazine-treated patients. Clozapine produced significantly greater improvement on the Brief Psychiatric Rating Scale, Clinical Global Impression Scale, and Nurses' Observation Scale for Inpatient Evaluation; this improvement included "negative" as well as positive symptom areas. Although no cases of agranulocytosis occurred during this relatively brief study, in our view, the apparently increased comparative risk requires that the use of clozapine be limited to selected treatment-resistant patients.

Overview

Integrity signals

Registry

Crossref · 10.1001/archpsyc.1988.01800330013001

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 4,156

Metadata

Authors
Kane, J.
Affiliations
Long Island Jewish Medical Center (US)
Corresponding author
Kane, John
Venue
Archives of General Psychiatry
Published
1988-09-01
Volume
45
Issue
9
Pages
789
ISSN
0003-990X (ISSN-L)
OpenAlex
W2085360366
Cited by
4,156
References
21
Citations by year
2026: 76 · 2025: 89 · 2024: 95 · 2023: 91 · 2022: 89 · 2021: 101 · 2020: 91 · 2019: 104 · 2018: 90 · 2017: 89 · 2016: 114 · 2015: 116 · 2014: 107 · 2013: 95 · 2012: 115
FWCI
57.71
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of General Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (MH41960, MH 47808, MH41954)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
clozapine, treatment-resistant schizophrenia, atypical antipsychotics, chlorpromazine, haloperidol, agranulocytosis, antipsychotic efficacy, negative symptoms, adverse drug reactions
MeSH terms
Adult, Chlorpromazine, Clinical Trials as Topic, Clozapine, Dibenzazepines, Double-Blind Method, Female, Haloperidol, Humans, Male, Middle Aged, Random Allocation, Schizophrenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine. https://app.cochat.ai/papers/10.1001/archpsyc.1988.01800330013001
The paper
Kane, J. (1988). Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1988.01800330013001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.